Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Thiele Website

Carol J. Thiele, Ph.D.

Selected Publications

1)  Tan F, Thiele CJ, Li Z.
Collapsin response mediator proteins: Potential diagnostic and prognostic biomarkers in cancers (Review).
Oncol Lett. 7: 1333-1340, 2014.
2)  Liu Z, Rader J, He S, Phung T, Thiele CJ.
CASZ1 inhibits cell cycle progression in neuroblastoma by restoring pRb activity.
Cell Cycle. 12: 2210-8, 2013.
3)  Tan F, Wahdan-Alaswad R, Yan S, Thiele CJ, Li Z.
Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.
Cancer Sci. 104: 1586-92, 2013.
4)  Yan S, Li Z, Thiele CJ.
Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.
Oncotarget. 4: 433-45, 2013.
5)  He S, Liu Z, Oh DY, Thiele CJ.
MYCN and the epigenome.
Front Oncol. 3: 1, 2013.
6)  Liu Z, Thiele CJ.
ALK and MYCN: when two oncogenes are better than one.
Cancer Cell. 21: 325-6, 2012.
7)  Virden RA, Thiele CJ, Liu Z.
Characterization of critical domains within the tumor suppressor CASZ1 required for transcriptional regulation and growth suppression.
Mol. Cell. Biol. 32: 1518-28, 2012.
8)  Li Z, Yan S, Attayan N, Ramalingam S, Thiele CJ.
Combination of an Allosteric Akt Inhibitor MK-2206 with Etoposide or Rapamycin Enhances the Antitumor Growth Effect in Neuroblastoma.
Clin. Cancer Res. 18: 3603-15, 2012.
9)  Lawlor ER, Thiele CJ.
Epigenetic changes in pediatric solid tumors: promising new targets.
Clin. Cancer Res. 18: 2768-79, 2012.
10)  Wang C, Liu Z, Woo CW, Li Z, Wang L, Wei JS, Marquez VE, Bates SE, Jin Q, Khan J, Ge K, Thiele CJ.
EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.
Cancer Res. 72: 315-24, 2012.
11)  Thiele CJ, Cohn SL.
Genetically InFormed Therapies--A.
Clin. Cancer Res. 18: 2735-9, 2012.
12)  Liu Z, Yang X, Li Z, McMahon C, Sizer C, Barenboim-Stapleton L, Bliskovsky V, Mock B, Ried T, London WB, Maris J, Khan J, Thiele CJ.
CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression.
Cell Death Differ. 18: 1174-83, 2011.
13)  Liu Z, Naranjo A, Thiele CJ.
CASZ1b, the short isoform of CASZ1 gene, coexpresses with CASZ1a during neurogenesis and suppresses neuroblastoma cell growth.
PLoS ONE. 6: e18557, 2011.
14)  Nakamura K, Tan F, Li Z, Thiele CJ.
NGF activation of TrkA induces vascular endothelial growth factor expression via induction of hypoxia-inducible factor-1α.
Mol. Cell. Neurosci. 46: 498-506, 2011.
15)  Li Z, Oh D, Nakamura K, Thiele CJ.
Perifosine-induced inhibition of akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo.
Cancer. 117: 5412-22, 2011.
16)  Li Z, Tan F, Liewehr DJ, Steinberg SM, Thiele CJ.
In vitro and in vivo inhibition of neuroblastoma tumor cell growth by AKT inhibitor perifosine.
J. Natl. Cancer Inst. 102: 758-70, 2010.
17)  Panicker J, Li Z, McMahon C, Sizer C, Steadman K, Piekarz R, Bates SE, Thiele CJ.
Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.
Cell Cycle. 9: 1830-8, 2010.
18)  Thiele CJ, Li Z, McKee AE.
'On Trk' The TrkB signal transduction pathway is an increasingly important target in cancer biology.
Clin. Cancer Res. 15: 5962-7, 2009.
19)  Reid G, Shan X, Coughlin C, Pawel B, Wexler L, Thiele CJ, Pinkus JL, Pinkus GS, Fleming MD, Grupp S, Vonderheide RH.
Interferon-gamma dependent infiltration of human T cells into neuroblastoma tumors in vivo.
Clin. Cancer Res. 15: 6602-8, 2009.
20)  Ahmed F, Tessarollo L, Thiele C, Mocchetti I.
Brain-derived neurotrophic factor modulates expression of chemokine receptors in the brain.
Brain Res. 1227: 1-11, 2008.
21)  Wei JS, Song YK, Durinck S, Chen Q, Cheuk AT, Tsang P, Zhang Q, Thiele CJ, Slack A, Shohet J, Khan J.
The MYCN oncogene is a direct target of miR-34a.
Oncogene. 27: 5204-13, 2008.
22)  Whiteford CC, Bilke S, Greer BT, Chen Q, Braunschweig TA, Cenacchi N, Wei JS, Smith MA, Houghton P, Morton C, Reynolds CP, Lock R, Gorlick R, Khanna C, Thiele CJ, Takikita M, Catchpoole D, Hewitt SM, Khan J.
Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis.
Cancer Res. 67: 32-40, 2007.
23)  Li Z, Zhang J, Liu Z, Woo C, Thiele CJ.
Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death.
Cell Death Differ. 14: 318-26, 2007.
24)  Li Z, Tan F, Thiele CJ.
Inactivation of glycogen synthase kinase-3beta contributes to brain-derived neutrophic factor/TrkB-induced resistance to chemotherapy in neuroblastoma cells.
Mol. Cancer Ther. 6: 3113-21, 2007.
25)  Hansford LM, McKee AE, Zhang L, George RE, Gerstle JT, Thorner PS, Smith KM, Look AT, Yeger H, Miller FD, Irwin MS, Thiele CJ, Kaplan DR.
Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell.
Cancer Res. 67: 11234-43, 2007.
26)  Song L, Ara T, Wu HW, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, Sposto R, Metelitsa LS.
Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
J. Clin. Invest. 117: 2702-12, 2007.
27)  Li Z, Thiele CJ.
Targeting Akt to increase the sensitivity of neuroblastoma to chemotherapy: lessons learned from the brain-derived neurotrophic factor/TrkB signal transduction pathway.
Expert Opin. Ther. Targets. 11: 1611-21, 2007.
28)  Woo C, Tan F, Cassano H, Lee J, Lee KC, Thiele CJ.
Use of RNA interference to elucidate the effect of MYCN on cell cycle in neuroblastoma.
Pediatr. Blood Cancer. 50: 208-12, 2007.
29)  Khanna C, Thiele C.
Poplack D, Pizzo P, eds.
Biology of Pediatric Tumors. In: Principles and Practive of Pediatric Oncology. Volume 5.
Philadelphia: Lippincott Williams & Wilkens; 2006. p. 86-117 [Book Chapter]
30)  Cellai I, Benvenuti S, Luciani P, Galli A, Ceni E, Simi L, Baglioni S, Muratori M, Ottanelli B, Serio M, Thiele CJ, Peri A.
Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells.
Br. J. Cancer. 95: 879-88, 2006.
31)  Nakamura K, Martin KC, Jackson JK, Beppu K, Woo CW, Thiele CJ.
Brain-derived neurotrophic factor activation of TrkB induces vascular endothelial growth factor expression via hypoxia-inducible factor-1alpha in neuroblastoma cells.
Cancer Res. 66: 4249-55, 2006.
32)  Liu Z, Yang X, Tan F, Cullion K, Thiele CJ.
Molecular cloning and characterization of human Castor, a novel human gene upregulated during cell differentiation.
Biochem. Biophys. Res. Commun. 344: 834-44, 2006.
33)  McKee AE, Thiele CJ.
Targeting caspase 8 to reduce the formation of metastases in neuroblastoma.
Expert Opin. Ther. Targets. 10: 703-8, 2006.
34)  Yang X, Zhang J, Jaboin J, Merchant M, Rajpal G, Mackall C, Thiele C.
The sensitivity of TNF-related apoptosis-inducing ligand in Neuroblastoma is increased by elevated levels of N-myc but not blocked by BDNF/TrkB activation.
World J. Pediatrics. 301-496-1543: 187-194, 2006.
35)  Thiele CJ, Reynolds CP.
Cheung NKV, Cohn SL, eds.
Differentiation and Retinoids. In: Neuroblastoma.
Berlin: Springer; 2005. p. 243-256 [Book Chapter]
36)  Li Z, Jaboin J, Dennis PA, Thiele CJ.
Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death.
Cancer Res. 65: 2070-5, 2005.
37)  Choi YL, Kim CJ, Matsuo T, Gaetano C, Falconi R, Suh YL, Kim SH, Shin YK, Park SH, Chi JG, Thiele CJ.
HUlip, a human homologue of unc-33-like phosphoprotein of Caenorhabditis elegans; Immunohistochemical localization in the developing human brain and patterns of expression in nervous system tumors.
J Neurooncol. 73: 19-27, 2005.
38)  Barenboim-Stapleton L, Yang X, Tsokos M, Wigginton JM, Padilla-Nash H, Ried T, Thiele CJ.
Pediatric pancreatoblastoma: histopathologic and cytogenetic characterization of tumor and derived cell line.
Cancer Genet Cytogenet. 157: 109-17, 2005.
39)  Beppu K, Nakamura K, Linehan WM, Rapisarda A, Thiele CJ.
Topotecan blocks hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells.
Cancer Res. 65: 4775-81, 2005.
40)  Lavoie JF, Lesauteur L, Kohn J, Wong J, Furtoss O, Thiele CJ, Miller FD, Kaplan DR.
TrkA Induces Apoptosis of Neuroblastoma Cells and Does So via a p53-dependent Mechanism.
J Biol Chem. 280: 29199-207, 2005.
41)  Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ.
Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
J Natl Cancer Inst. 96: 46-55, 2004.
42)  Li Z, Ding M, Thiele CJ, Luo J.
Ethanol inhibits brain-derived neurotrophic factor-mediated intracellular signaling and activator protein-1 activation in cerebellar granule neurons.
Neuroscience. 126: 149-62, 2004.
43)  Chen G, Bower KA, Ma C, Fang S, Thiele CJ, Luo J.
Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death.
FASEB J. 18: 1162-4, 2004.
44)  Merchant MS, Yang X, Melchionda F, Romero M, Klein R, Thiele CJ, Tsokos M, Kontny HU, Mackall CL.
Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma.
Cancer Res. 64: 8349-56, 2004.
45)  Woo CW, Lucarelli E, Thiele CJ.
NGF activation of TrkA decreases N-myc expression via MAPK path leading to a decrease in neuroblastoma cell number.
Oncogene. 23: 1522-30, 2004.
46)  Jaboin J, Hong A, Kim CJ, Thiele CJ.
Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma.
Cancer Lett. 193: 109-14, 2003.
47)  Yang X, Merchant MS, Romero ME, Tsokos M, Wexler LH, Kontny U, Mackall CL, Thiele CJ.
Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB.
Cancer Res. 63: 1122-9, 2003.
48)  Nakamura M, Matsuo T, Stauffer J, Neckers L, Thiele CJ.
Retinoic acid decreases targeting of p27 for degradation via an N-myc-dependent decrease in p27 phosphorylation and an N-myc-independent decrease in Skp2.
Cell Death Differ. 10: 230-9, 2003.
49)  Yang X, Thiele CJ.
Targeting the tumor necrosis factor-related apoptosis-inducing ligand path in neuroblastoma.
Cancer Lett. 197: 137-43, 2003.
50)  Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ.
Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis.
In Vivo. 16: 77-85, 2002.
51)  Jaboin J, Kim CJ, Kaplan DR, Thiele CJ.
Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway.
Cancer Res. 62: 6756-63, 2002.
52)  Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, Bates SE, Thiele CJ.
MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
Cancer Res. 62: 6108-15, 2002.
53)  Merchant MS, Woo CW, Mackall CL, Thiele CJ.
Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
J Natl Cancer Inst. 94: 1673-9, 2002.
54)  Cerignoli F, Guo X, Cardinali B, Rinaldi C, Casaletto J, Frati L, Screpanti I, Gudas LJ, Gulino A, Thiele CJ, Giannini G.
retSDR1, a short-chain retinol dehydrogenase/reductase, is retinoic acid-inducible and frequently deleted in human neuroblastoma cell lines.
Cancer Res. 62: 1196-204, 2002.
55)  Matsuo T, Seth P, Thiele CJ.
Increased expression of p27Kip1 arrests neuroblastoma cell growth.
Med Pediatr Oncol. 36: 97-9, 2001.
56)  Thiele CJ, Gore S, Collins S, Waxman S, Miller W.
Differentiate or die: the view from Montreal.
Cell Death Differ. 7: 1014-7, 2000.
57)  Matsuo T, Stauffer JK, Walker RL, Meltzer P, Thiele CJ.
Structure and promoter analysis of the human unc-33-like phosphoprotein gene. E-box required for maximal expression in neuroblastoma and myoblasts.
J. Biol. Chem. 275: 16560-8, 2000.
58)  Matsuo T, Stauffer JK, Walker RL, Meltzer P, Thiele CJ.
Structure and promoter analysis of the human unc-33-like phosphoprotein gene: E-box required for maximal expression in neuroblastoma and myoblast.
J Biol Chem. 275: 25052, 2000.
59)  Ensoli F, Fiorelli V, DeCristofaro M, Santini Muratori D, Novi A, Vannelli B, Thiele CJ, Luzi G, Aiuti F.
Inflammatory cytokines and HIV-1-associated neurodegeneration: oncostatin-M produced by mononuclear cells from HIV-1-infected individuals induces apoptosis of primary neurons.
J. Immunol. 162: 6268-77, 1999.
60)  Kim CJ, Chi JG, Thiele CJ.
Insulin-like growth factor-II expression is down-regulated in TrkA-transfected SK-N-AS neuroblastoma cells.
Lab. Invest. 79: 1007-13, 1999.
61)  Hahm KB, Cho K, Lee C, Im YH, Chang J, Choi SG, Sorensen PH, Thiele CJ, Kim SJ.
Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
Nat Genet. 23: 222-7, 1999.
62)  Kim CJ, Matsuo T, Lee KH, Thiele CJ.
Up-regulation of insulin-like growth factor-II expression is a feature of TrkA but not TrkB activation in SH-SY5Y neuroblastoma cells.
Am. J. Pathol. 155: 1661-70, 1999.
63)  Ensoli F, Fiorelli V, Vannelli B, Barni T, De Cristofaro M, Ensoli B, Thiele CJ.
Basic fibroblast growth factor supports human olfactory neurogenesis by autocrine/paracrine mechanisms.
Neuroscience. 86: 881-93, 1998.
64)  Thiele CJ, Waxman S, Chomienne C.
Differentiation or death: the view from Versailles.
Cell Death Differ. 5: 716-8, 1998.
65)  Tsao H, Benoit E, Sober AJ, Thiele C, Haluska FG.
Novel mutations in the p16/CDKN2A binding region of the cyclin-dependent kinase-4 gene.
Cancer Res. 58: 109-13, 1998.
66)  Matsuo T, Thiele CJ.
p27Kip1: a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line.
Oncogene. 16: 3337-43, 1998.
67)  Giannini G, Dawson MI, Zhang X, Thiele CJ.
Activation of three distinct RXR/RAR heterodimers induces growth arrest and differentiation of neuroblastoma cells.
J. Biol. Chem. 272: 26693-701, 1997.
68)  Lucarelli E, Kaplan D, Thiele CJ.
Activation of trk-A but not trk-B signal transduction pathway inhibits growth of neuroblastoma cells.
Eur. J. Cancer. 33: 2068-70, 1997.
69)  Ensoli F, Wang H, Fiorelli V, Zeichner SL, De Cristofaro MR, Luzi G, Thiele CJ.
HIV-1 infection and the developing nervous system: lineage-specific regulation of viral gene expression and replication in distinct neuronal precursors.
J. Neurovirol. 3: 290-8, 1997.
70)  Gaetano C, Matsuo T, Thiele CJ.
Identification and characterization of a retinoic acid-regulated human homologue of the unc-33-like phosphoprotein gene (hUlip) from neuroblastoma cells.
J. Biol. Chem. 272: 12195-201, 1997.
71)  Haluska FG, Thiele C, Goldstein A, Tsao H, Benoit EP, Housman D.
Lack of phospholipase A2 mutations in neuroblastoma, melanoma and colon-cancer cell lines.
Int. J. Cancer. 72: 337-9, 1997.
72)  Goodman LA, Liu BC, Thiele CJ, Schmidt ML, Cohn SL, Yamashiro JM, Pai DS, Ikegaki N, Wada RK.
Modulation of N-myc expression alters the invasiveness of neuroblastoma.
Clin. Exp. Metastasis. 15: 130-9, 1997.
73)  Melino G, Thiele CJ, Knight RA, Piacentini M.
Retinoids and the control of growth/death decisions in human neuroblastoma cell lines.
J. Neurooncol. 31: 65-83, 1997.
74)  Miller MJ, Martínez A, Unsworth EJ, Thiele CJ, Moody TW, Elsasser T, Cuttitta F.
Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor.
J. Biol. Chem. 271: 23345-51, 1996.
75)  Scala S, Wosikowski K, Giannakakou P, Valle P, Biedler JL, Spengler BA, Lucarelli E, Bates SE, Thiele CJ.
Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity.
Cancer Res. 56: 3737-42, 1996.
76)  Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR, Thiele CJ.
Expression of brain-derived neurotrophic factor and p145TrkB affects survival, differentiation, and invasiveness of human neuroblastoma cells.
Cancer Res. 55: 1798-806, 1995.
77)  Ensoli F, Cafaro A, Fiorelli V, Vannelli B, Ensoli B, Thiele CJ.
HIV-1 infection of primary human neuroblasts.
Virology. 210: 221-5, 1995.
78)  Cohen PS, Letterio JJ, Gaetano C, Chan J, Matsumoto K, Sporn MB, Thiele CJ.
Induction of transforming growth factor beta 1 and its receptors during all-trans-retinoic acid (RA) treatment of RA-responsive human neuroblastoma cell lines.
Cancer Res. 55: 2380-6, 1995.
79)  Vannelli GB, Ensoli F, Zonefrati R, Kubota Y, Arcangeli A, Becchetti A, Camici G, Barni T, Thiele CJ, Balboni GC.
Neuroblast long-term cell cultures from human fetal olfactory epithelium respond to odors.
J. Neurosci. 15: 4382-94, 1995.
80)  Lucarelli E, Kaplan DR, Thiele CJ.
Selective regulation of TrkA and TrkB receptors by retinoic acid and interferon-gamma in human neuroblastoma cell lines.
J. Biol. Chem. 270: 24725-31, 1995.
81)  Ensoli F, Ensoli B, Thiele CJ.
HIV-1 gene expression and replication in neuronal and glial cell lines with immature phenotype: effects of nerve growth factor.
Virology. 200: 668-76, 1994.
82)  Maggi M, Baldi E, Finetti G, Franceschelli F, Brocchi A, Lanzillotti R, Serio M, Camboni MG, Thiele CJ.
Identification, characterization, and biological activity of somatostatin receptors in human neuroblastoma cell lines.
Cancer Res. 54: 124-33, 1994.
83)  Lucarelli E, Kaplan D, Matsumoto K, Sickafuse S, Thiele CJ.
Retinoic acid induced differentiation is mediated by trkB receptors.
Prog. Clin. Biol. Res. 385: 185-98, 1994.
84)  Kaplan DR, Matsumoto K, Lucarelli E, Thiele CJ.
Induction of TrkB by retinoic acid mediates biologic responsiveness to BDNF and differentiation of human neuroblastoma cells. Eukaryotic Signal Transduction Group.
Neuron. 11: 321-31, 1993.
85)  Melino G, Knight RA, Thiele CJ.
New insight on the biology of neuroectodermal tumors. Workshop report from the University of Rome Tor Vergata and the IDI-IRCCS on the genetics and control of growth, differentiation, and programmed cell death.
Cancer Res. 53: 926-8, 1993.
86)  Collum RG, Fisher PE, Datta M, Mellis S, Thiele C, Huebner K, Croce CM, Israel MA, Theil T, Moroy T.
A novel POU homeodomain gene specifically expressed in cells of the developing mammalian nervous system.
Nucleic Acids Res. 20: 4919-25, 1992.
87)  Gaetano C, Matsumoto K, Thiele CJ.
In vitro activation of distinct molecular and cellular phenotypes after induction of differentiation in a human neuroblastoma cell line.
Cancer Res. 52: 4402-7, 1992.
88)  Matsumoto K, Gaetano C, Daughaday WH, Thiele CJ.
Retinoic acid regulates insulin-like growth factor II expression in a neuroblastoma cell line.
Endocrinology. 130: 3669-76, 1992.
89)  Thiele CJ.
Biology of pediatric peripheral neuroectodermal tumors.
Cancer Metastasis Rev. 10: 311-9, 1991.
90)  Kidowaki T, Thiele CJ, Kleinman HK, Israel MA.
Matrix proteins induce neuroblastoma cell differentiation without altering cell growth.
Pathobiology. 59: 316-23, 1991.
91)  Helman LJ, Thiele CJ.
New insights into the causes of cancer.
Pediatr. Clin. North Am. 38: 201-21, 1991.
92)  Thiele CJ.
Patterns of regulation of nuclear proto-oncogenes MYCN and MYB in retinoic acid treated neuroblastoma cells.
Prog. Clin. Biol. Res. 366: 151-6, 1991.
93)  Gaetano C, Matsumoto K, Thiele CJ.
Retinoic acid negatively regulates p34cdc2 expression during human neuroblastoma differentiation.
Cell Growth Differ. 2: 487-93, 1991.
94)  Gaetano C, Matsumoto K, Thiele CJ.
Retinoic acid resistant neuroblastoma cells and the expression of insulin-like growth factor-II.
Prog. Clin. Biol. Res. 366: 165-72, 1991.
95)  Sacchi N, Wendtner CM, Thiele CJ.
Single-cell detection of ets-1 transcripts in human neuroectodermal cells.
Oncogene. 6: 2149-54, 1991.
96)  Cohen PS, Cooper MJ, Helman LJ, Thiele CJ, Seeger RC, Israel MA.
Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors.
Cancer Res. 50: 6055-61, 1990.
97)  Thiele CJ.
Pediatric peripheral neuroectodermal tumors, oncogenes, and differentiation.
Cancer Invest. 8: 629-39, 1990.
98)  Feltner DE, Cooper M, Weber J, Israel MA, Thiele CJ.
Expression of class I histocompatibility antigens in neuroectodermal tumors is independent of the expression of a transfected neuroblastoma myc gene.
J. Immunol. 143: 4292-9, 1989.
99)  Thiele CJ, Cazenave L, Bolen JB, Israel MA.
Developmentally regulated genes in neuroblastoma.
Prog. Clin. Biol. Res. 271: 185-94, 1988.
100)  McKeon C, Thiele CJ, Ross RA, Kwan M, Triche TJ, Miser JS, Israel MA.
Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma.
Cancer Res. 48: 4307-11, 1988.
101)  Thiele CJ, Cohen PS, Israel MA.
Regulation of c-myb expression in human neuroblastoma cells during retinoic acid-induced differentiation.
Mol. Cell. Biol. 8: 1677-83, 1988.
102)  Thiele CJ, Israel MA.
Regulation of N-myc expression is a critical event controlling the ability of human neuroblasts to differentiate.
Exp. Cell Biol. 56: 321-33, 1988.
103)  Thiele CJ, Deutsch LA, Israel MA.
The expression of multiple proto-oncogenes is differentially regulated during retinoic acid induced maturation of human neuroblastoma cell lines.
Oncogene. 3: 281-8, 1988.
104)  Thiele CJ, McKeon C, Triche TJ, Ross RA, Reynolds CP, Israel MA.
Differential protooncogene expression characterizes histopathologically indistinguishable tumors of the peripheral nervous system.
J. Clin. Invest. 80: 804-11, 1987.
105)  Helman LJ, Thiele CJ, Linehan WM, Nelkin BD, Baylin SB, Israel MA.
Molecular markers of neuroendocrine development and evidence of environmental regulation.
Proc. Natl. Acad. Sci. U.S.A. 84: 2336-9, 1987.
106)  Thiele CJ, Whang-Peng J, Kao-Shan CS, Miser J, Israel MA.
Translocation of c-sis protooncogene in peripheral neuroepithelioma.
Cancer Genet. Cytogenet. 24: 119-28, 1987.
107)  Rosen N, Reynolds CP, Thiele CJ, Biedler JL, Israel MA.
Increased N-myc expression following progressive growth of human neuroblastoma.
Cancer Res. 46: 4139-42, 1986.
108)  Thiele CJ, Reynolds CP, Israel MA.
Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma.
Nature. 313: 404-6, 1985.
109)  Israel MA, Thiele C, Whang-Peng J, Kao-Shan CS, Triche TJ, Miser J.
Peripheral neuroepithelioma: genetic analysis of tumor derived cell lines.
Prog. Clin. Biol. Res. 175: 161-70, 1985.
110)  Bolen JB, Thiele CJ, Israel MA, Yonemoto W, Lipsich LA, Brugge JS.
Enhancement of cellular src gene product associated tyrosyl kinase activity following polyoma virus infection and transformation.
Cell. 38: 767-77, 1984.
111)  Mushinski JF, Thiele CJ, Owens JD, Blattner FR, Shen AL, Tucker PW, Fitzmaurice L.
Genetic aspects of IgD expression: II. Multiple forms of delta chain mRNA in normal mouse spleen, mouse B-cell lymphomas and mouse and human myelomas.
Ann. N. Y. Acad. Sci. 399: 15-25, 1982.
112)  Thiele CJ, Morrow CD, Stevens RH.
Human IgA antibody and immunoglobulin production after in vivo tetanus toxoid immunization: size and surface membrane phenotype analysis.
J. Clin. Immunol. 2: 327-34, 1982.
113)  Saxon A, Thiele CJ, Moroz C, Stevens RH.
Adenosine receptor lymphocytes in humoral immunodeficiency.
J. Clin. Immunol. 1: 131-6, 1981.
114)  Stevens RH, Macy E, Thiele CJ.
Evidence that pokeweed-mitogen-reactive B cells are pre-committed in vivo to the high-rate secretion of a single immunoglobulin isotype in vitro.
Scand. J. Immunol. 14: 449-57, 1981.
115)  Thiele CJ, Stevens RH.
Expression of surface membrane IgG on pokeweed mitogen-reactive anti-tetanus toxoid antibody-producing cells.
J. Clin. Immunol. 1: 174-80, 1981.
116)  Thiele CJ, Morrow CD, Stevens RH.
Multiple subsets of anti-tetanus toxoid antibody-producing cells in human peripheral blood differ by size, expression of membrane receptors, and mitogen reactivity.
J. Immunol. 126: 1146-53, 1981.
117)  Thiele CJ, Stevens RH.
Antibody potential of human peripheral blood lymphocytes differentially expressing surface membrane IgM.
J. Immunol. 124: 1898-904, 1980.
118)  Stevens RH, Thiele CJ, Saxon A.
The production of a soluble human T-lymphocyte derived factor which substitutes for helper T lymphocytes in the in vitro production of immunoglobulin.
Immunology. 36: 407-13, 1979.
Click Here to View Collapsed Bibliography.

This page was last updated on 5/19/2014.